Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems

McDonald, S; Rubin, P; Phillips, T L

doi:10.1016/0360-3016(94)00429-O

Title: Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems

Full Record
Other Related Research

Abstract

Toxicity of the respiratory system is a common side effect and complication of anticancer therapy that can result in significant morbidity. The range of respiratory compromise can extend from acute lethal events to degrees of chronic pulmonary decompensation, manifesting years after the initial cancer therapy. This review examines the anatomic-histologic background of the lung and the normal functional anatomic unit. The pathophysiology of radiation and chemotherapy induced lung injury is discussed as well as the associated clinical syndromes. Radiation tolerance doses and volumes are assessed in addition to chemotherapy tolerance and risk factors and radiation-chemotherapy interactions. There are a variety of measurable endpoints for detection and screening. Because of the wide range of available quantitative tests, it would seem that the measurement of impaired lung function is possible. The development of staging systems for acute and late toxicity is discussed an a new staging system for Late Effects in Normal Tissues :(LENT) is proposed. 115 refs., 2 figs., 9 tabs.

Authors:

McDonald, S; Rubin, P ^[1]; Phillips, T L ^[2]

Univ. of Rochester Cancer Center, NY (United States)
Univ. of California, San Francisco, CA (United States); and other

Publication Date:: Thu Mar 30 00:00:00 EST 1995

OSTI Identifier:: 90883

Resource Type:: Journal Article

Journal Name:: International Journal of Radiation Oncology, Biology and Physics

Additional Journal Information:: Journal Volume: 31; Journal Issue: 5; Other Information: PBD: 30 Mar 1995

Country of Publication:: United States

Language:: English

Subject:: 55 BIOLOGY AND MEDICINE, BASIC STUDIES; 56 BIOLOGY AND MEDICINE, APPLIED STUDIES; RESPIRATORY SYSTEM; SIDE EFFECTS; BIOLOGICAL RADIATION EFFECTS; COMBINED THERAPY; TOLERANCE; DOSE-RESPONSE RELATIONSHIPS; LUNGS; NEOPLASMS

Citation Formats


                    McDonald, S, Rubin, P, and Phillips, T L. Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems.  United States: N. p., 1995. 
        Web.  doi:10.1016/0360-3016(94)00429-O.

Copy to clipboard


                    McDonald, S, Rubin, P, & Phillips, T L. Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems.  United States.  https://doi.org/10.1016/0360-3016(94)00429-O

Copy to clipboard


                    McDonald, S, Rubin, P, and Phillips, T L. 1995.  
        "Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems".  United States.  https://doi.org/10.1016/0360-3016(94)00429-O.

Copy to clipboard


                    
@article{osti_90883,

  title        = {Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems},

  author       = {McDonald, S and Rubin, P and Phillips, T L},

  abstractNote = {Toxicity of the respiratory system is a common side effect and complication of anticancer therapy that can result in significant morbidity. The range of respiratory compromise can extend from acute lethal events to degrees of chronic pulmonary decompensation, manifesting years after the initial cancer therapy. This review examines the anatomic-histologic background of the lung and the normal functional anatomic unit. The pathophysiology of radiation and chemotherapy induced lung injury is discussed as well as the associated clinical syndromes. Radiation tolerance doses and volumes are assessed in addition to chemotherapy tolerance and risk factors and radiation-chemotherapy interactions. There are a variety of measurable endpoints for detection and screening. Because of the wide range of available quantitative tests, it would seem that the measurement of impaired lung function is possible. The development of staging systems for acute and late toxicity is discussed an a new staging system for Late Effects in Normal Tissues :(LENT) is proposed. 115 refs., 2 figs., 9 tabs.},

  doi          = {10.1016/0360-3016(94)00429-O},

  url          = {https://www.osti.gov/biblio/90883},
  journal      = {International Journal of Radiation Oncology, Biology and Physics},
number       = 5,

  volume       = 31,

  place        = {United States},

  year         = {Thu Mar 30 00:00:00 EST 1995},

  month        = {Thu Mar 30 00:00:00 EST 1995}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1016/0360-3016(94)00429-O

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Prospective, Risk-Adapted Strategy of Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: Results of a Phase II Trial

Journal Article Bral, Samuel; Gevaert, Thierry; Linthout, Nadine; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Validation of a prospective, risk-adapted strategy for early-stage non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Methods and Materials: Patients with a T1-3N0M0 (American Joint Committee on Cancer 6th edition) NSCLC were accrued. Using the Radiation Therapy Oncology Group definition, patients were treated to a total dose of 60,Gy in three fractions for peripherally located lesions and four fractions for centrally located lesions. The primary endpoint was toxicity, graded according to the Radiation Therapy Oncology Group acute and late morbidity scoring system, and the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. Secondarymore »« less
https://doi.org/10.1016/j.ijrobp.2010.04.056
A Phase I/II Radiation Dose Escalation Study With Concurrent Chemotherapy for Patients With Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117

Journal Article Moughan, Jennifer; Graham, Mary; Byhardt, Roger; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: In preparation for a Phase III comparison of high-dose versus standard-dose radiation therapy, this Phase I/II study was initiated to establish the maximum tolerated dose of radiation therapy in the setting of concurrent chemotherapy, using three-dimensional conformal radiation therapy for non-small-cell lung cancer. Methods and Materials: Eligibility included patients with histologically proven, unresectable Stages I to III non-small-cell lung cancer. Concurrent chemotherapy consisted of paclitaxel, 50 mg/m{sup 2}, and carboplatin, AUC of 2, given weekly. The radiation dose was to be sequentially intensified by increasing the daily fraction size, starting from 75.25 Gy/35 fractions. Results: The Phase I portionmore »« less
https://doi.org/10.1016/j.ijrobp.2009.04.029
Image Guided Hypofractionated 3-Dimensional Radiation Therapy in Patients With Inoperable Advanced Stage Non-Small Cell Lung Cancer

Journal Article Osti, Mattia; Agolli, Linda; Valeriani, Maurizio; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Hypofractionated radiation therapy (HypoRT) can potentially improve local control with a higher biological effect and shorter overall treatment time. Response, local control, toxicity rates, and survival rates were evaluated in patients affected by inoperable advanced stage non-small cell lung cancer (NSCLC) who received HypoRT. Methods and Materials: Thirty patients with advanced NSCLC were enrolled; 27% had stage IIIA, 50% had stage IIIB, and 23% had stage IV disease. All patients underwent HypoRT with a prescribed total dose of 60 Gy in 20 fractions of 3 Gy each. Radiation treatment was delivered using an image guided radiation therapy technique tomore »« less
https://doi.org/10.1016/J.IJROBP.2012.10.012
A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study

Journal Article Henderson, Randal; Pham, Dat; Cury, James; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Proton therapy has been shown to reduce radiation dose to organs at risk (OAR) and could be used to safely escalate the radiation dose. We analyzed outcomes in a group of phase 2 study patients treated with dose-escalated proton therapy with concurrent chemotherapy for stage 3 non-small cell lung cancer (NSCLC). Methods and Materials: From 2009 through 2013, LU02, a phase 2 trial of proton therapy delivering 74 to 80 Gy at 2 Gy/fraction with concurrent chemotherapy for stage 3 NSCLC, was opened to accrual at our institution. Due to slow accrual and competing trials, the study was closed after justmore »« less
https://doi.org/10.1016/J.IJROBP.2015.11.004
Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience

Journal Article Zhiqin, Jiang; Kunyu, Yang; Komaki, Ritsuko; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up. Methods and Materials: Patients in this retrospective review were 165 patients who began definitive radiotherapy, with or without chemotherapy, for newly diagnosed, pathologically confirmed NSCLC to a dose of {>=}60 Gy from 2005 to 2006. Early and late toxicities assessed included treatment-related pneumonitis (TRP), pulmonary fibrosis, esophagitis, and esophageal stricture, scored mainly according to the Common Terminology Criteria for Adverse Events 3.0. Other variables monitored were radiation-associated dermatitismore »« less
https://doi.org/10.1016/J.IJROBP.2011.06.1963

Similar Records